BeOne Medicines (ONC) Net Cash Flow (2015 - 2026)

BeOne Medicines (ONC) has reported Net Cash Flow for 12 consecutive years, with $224.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 301.06% year-over-year to $224.5 million; the TTM figure through Mar 2026 stood at $2.2 billion (up 995.0% YoY), while the FY2025 annual figure was $1.9 billion, up 485.62% from the prior year.
• Net Cash Flow fell to $224.5 million in Q1 2026 per ONC's latest filing, from $475.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $1.3 billion in Q3 2025 and bottomed at -$390.0 million in Q4 2022.
• Historically, Net Cash Flow has averaged $30.6 million across 5 years, with a median of -$37.4 million in 2022.
• Annual changes were most pronounced in 2023 — Net Cash Flow sank 815.09% — and 2025, when it surged 2172.2%.
• BeOne Medicines' Net Cash Flow stood at -$390.0 million in 2022, then soared by 116.11% to $62.8 million in 2023, then sank by 136.56% to -$23.0 million in 2024, then soared by 2172.2% to $475.9 million in 2025, then tumbled by 52.84% to $224.5 million in 2026.
• Business Quant data shows ONC's Net Cash Flow at $224.5 million in Q1 2026, $475.9 million in Q4 2025, and $1.3 billion in Q3 2025.